{
    "nctId": "NCT00796107",
    "briefTitle": "A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer",
    "officialTitle": "An Open Label Study to Evaluate the Safety, Tolerability and Effect on Tumor Response of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer.",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 6,
    "primaryOutcomeMeasure": "Objective Tumor Response (Part 2)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* postmenopausal female patients;\n* stage IV or locally advanced breast cancer;\n* measurable disease;\n* letrozole failure (Part 2);\n* Eastern Cooperative Oncology Group (ECOG) performance status \\<=2.\n\nExclusion Criteria:\n\n* previous chemotherapy for metastatic breast cancer;\n* concurrent antibody or immunotherapy for advanced disease, within 4 weeks prior to receipt of study drug;\n* history of primary malignancy in 5 years prior to study, excluding adequately treated basal or squamous cell cancer of skin, or cancer in situ of cervix;\n* concurrent radiotherapy, or radiotherapy within 28 days prior to receipt of study drug.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}